JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Search

PerkinElmer Inc

Suletud

SektorTervishoid

0

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Põhinäitajad

By Trading Economics

Sissetulek

-8.6M

47M

Müük

-21M

699M

P/E

Sektori keskmine

50.083

37.003

Aktsiakasum

0.4

Dividenditootlus

0.28

Kasumimarginaal

6.675

Töötajad

11,000

EBITDA

-14M

181M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+22.06% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.28%

2.25%

Järgmine dividendimakse kuupäev

7. nov 2025

Järgmine aktsia dividendi kuupäev (ex-date)

16. jaan 2026

Turustatistika

By TradingEconomics

Turukapital

584M

11B

Eelmine avamishind

0

Eelmine sulgemishind

0

Uudiste sentiment

By Acuity

34%

66%

100 / 373 Pingereas Healthcare

PerkinElmer Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

31. okt 2025, 17:40 UTC

Omandamised, ülevõtmised, äriostud

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

31. okt 2025, 23:09 UTC

Tulu

Review & Preview: October Surprise -- Barrons.com

31. okt 2025, 22:44 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31. okt 2025, 21:25 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31. okt 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31. okt 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31. okt 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31. okt 2025, 21:12 UTC

Omandamised, ülevõtmised, äriostud

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31. okt 2025, 20:51 UTC

Omandamised, ülevõtmised, äriostud

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

31. okt 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31. okt 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. okt 2025, 20:50 UTC

Market Talk
Tulu

Auto & Transport Roundup: Market Talk

31. okt 2025, 20:46 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31. okt 2025, 20:22 UTC

Tulu

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

31. okt 2025, 20:02 UTC

Tulu

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

31. okt 2025, 19:55 UTC

Market Talk

Crude Futures Fall for Third Straight Month -- Market Talk

31. okt 2025, 19:54 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31. okt 2025, 19:54 UTC

Omandamised, ülevõtmised, äriostud

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31. okt 2025, 19:26 UTC

Market Talk

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

31. okt 2025, 18:30 UTC

Tulu

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31. okt 2025, 18:23 UTC

Market Talk

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

31. okt 2025, 18:09 UTC

Tulu

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31. okt 2025, 18:08 UTC

Tulu

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31. okt 2025, 17:36 UTC

Market Talk

Grain Futures Shrug Off Stronger Dollar -- Market Talk

31. okt 2025, 17:31 UTC

Market Talk

U.S. Oil Rig Count Falls, Natural Gas Rig Count Rises -- Market Talk

31. okt 2025, 17:16 UTC

Omandamised, ülevõtmised, äriostud

Orange: Acquisition Likely Completed in First Half Next Year

31. okt 2025, 17:15 UTC

Omandamised, ülevõtmised, äriostud

Orange: Agreement Set to Be Signed By Year-Out

31. okt 2025, 17:14 UTC

Omandamised, ülevõtmised, äriostud

Orange: Acquisition Will Strengthen Position in Spain

31. okt 2025, 17:13 UTC

Omandamised, ülevõtmised, äriostud

Orange Will Be Sole Owner of Spain's MasOrange Following Acquisition of Lorca's Stake

31. okt 2025, 17:12 UTC

Omandamised, ülevõtmised, äriostud

Orange Reaches Deal to Buy Lorca's 50% Stake in MasOrange for EUR4.25B

Võrdlus sarnastega

Hinnamuutus

PerkinElmer Inc Prognoos

Hinnasiht

By TipRanks

22.06% tõus

12 kuu keskmine prognoos

Keskmine 111.1 USD  22.06%

Kõrge 125 USD

Madal 100 USD

Põhineb 11 Wall Streeti analüütiku instrumendi PerkinElmer Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

11 ratings

8

Osta

3

Hoia

0

Müü

Sentiment

By Acuity

100 / 373 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat